Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

Non-small cell lung cancer (NSCLC) is a major public health problem. New treatments as immunotherapy can improve prognosis of patients with NCLC tumors. Nevertheless, no robust biomarker is actually available. The hypothesis of the trial is to realize a longitudinal molecular monitoring of NSCLC patients treated by immunotherapy using a quantitative analysis of cell-free DNA. The primary purposes is to study the predictive value of quantification of cell-free DNA at the first reevaluation time, on the clinical benefit, in NSCLC patients treated by immunotherapy (regardless of line, or associ

Trial Details

NCT ID
NCT04720339
Phase
NA
Sponsor
University Hospital, Strasbourg, France
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Molecular monitoring by quantification of cell-free DNA
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Colmar, France|48.08078,7.35584
  • Dijon, France|47.31344,5.01391
  • Dijon, France|47.31344,5.01391
  • Mulhouse, France|47.75205,7.32866

Key Eligibility Criteria

  • age over 18
  • informed of the objectives of the project and signed consent
  • non small cell lung cancer, stage IIIA, IIIB or IV
  • PS (WHO performance status) \< or =2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →